This article is more than 5 years old. Information may no longer be current.

Omeros reports $3.2 million in revenue in second quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Omeros reported revenue of $3.2 million in the second quarter, which included $3.1 million in Omidria sales and $62,000 in grant revenue, according to a press release.

Revenue totaled $45,000 in the second quarter of 2014.

Total costs and expenses were reported at $19.2 million in the second quarter compared with $17.3 million in the second quarter of the previous year. The increase was attributed to sales and marketing costs for the broad U.S. commercial launch of Omidria (phenylephrine 1% and ketorolac 0.3%).

Net loss was reported at $16.7 million, or $0.44 per share, in the second quarter compared with $18 million, or $0.53 per share, in the second quarter of the previous year.